Inflammatory mediators and insulin resistance in obesity: Role of nuclear receptor signaling in macrophages

Mediators of Inflammation

Volumn 2010, Issue , 2010, Pages

  Fuentes, Lucía ^a   Roszer, Tamás ^a   Ricote, Mercedes ^a  

^a CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CELL NUCLEUS RECEPTOR; CHEMOKINE RECEPTOR CCR2; CYTOKINE; GLYCOPROTEIN P 15095; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN SENSITIZING AGENT; LIVER X RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STRESS ACTIVATED PROTEIN KINASE; AUTACOID; ORPHAN NUCLEAR RECEPTOR;

ADIPOSE TISSUE; BODY MASS; BONE DENSITY; CHRONIC INFLAMMATION; COMORBIDITY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE COURSE; FATTY LIVER; HUMAN; IMMUNE RESPONSE; INSULIN RESISTANCE; KUPFFER CELL; LIVER FIBROSIS; MACROPHAGE ACTIVATION; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPENIA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; WEIGHT REDUCTION; ANIMAL; CYTOLOGY; MACROPHAGE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; BONE RESORPTION; FATTY LIVER; HUMANS; INFLAMMATION MEDIATORS; INSULIN RESISTANCE; MACROPHAGES; OBESITY; ORPHAN NUCLEAR RECEPTORS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SIGNAL TRANSDUCTION;

EID: 77953493182     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2010/219583     Document Type: Review

References (112)

1. Greenfield J. R., Campbell L. V., Relationship between inflammation, insulin resistance and type 2 diabetes: cause or effect? Current Diabetes Reviews 2006 2 2 195 211
2. Ahmed L. A., Joakimsen R. M., Berntsen G. K., Fonnebo V., Schirmer H., Diabetes mellitus and the risk of non-vertebral fractures: the Tromso study Osteoporosis International 2006 17 4 495 500
3. Jaskiewicz K., Rzepko R., Sledzinski Z., Fibrogenesis in fatty liver associated with obesity and diabetes mellitus type 2 Digestive Diseases and Sciences 2008 53 3 785 788
4. Mak K.-H., Ma S., Heng D., Impact of sex, metabolic syndrome, and diabetes mellitus on cardiovascular events American Journal of Cardiology 2007 100 2 227 233
5. Hamdy O., Porramatikul S., Al-Ozairi E., Metabolic obesity: the paradox between visceral and subcutaneous fat Current Diabetes Reviews 2006 2 4 367 373
6. Henkin L., Bergman R. N., Bowden D. W., Genetic epidemiology of insulin resistance and visceral adiposity: the IRAS Family Study design and methods Annals of Epidemiology 2003 13 4 211 217
7. Chiriboga D. E., Ma Y., Li W., Gender differences in predictors of body weight and body weight change in healthy adults Obesity 2008 16 1 137 145
8. Thorand B., Baumert J., Kolb H., Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 19842002 Diabetes Care 2007 30 4 854 860
9. Woods S. C., Gotoh K., Clegg D. J., Gender differences in the control of energy homeostasis Experimental Biology and Medicine 2003 228 10 1175 1180
10. Assimacopoulos-Jeannet F., Fat storage in pancreas and in insulin-sensitive tissues in pathogenesis of type 2 diabetes International Journal of Obesity 2004 28 supplement 4 S53 S57
11. Heikkinen S., Auwerx J., Argmann C. A., PPAR in human and mouse physiology Biochimica et Biophysica Acta 2007 1771 8 999 1013
12. Weinberg J. M., Lipotoxicity Kidney International 2006 70 9 1560 1566
13. Shoelson S. E., Lee J., Goldfine A. B., Inflammation and insulin resistance Journal of Clinical Investigation 2006 116 7 1793 1801
14. Weisberg S. P., McCann D., Desai M., Rosenbaum M., Leibel R. L., Ferrante A. W. Jr., Obesity is associated with macrophage accumulation in adipose tissue Journal of Clinical Investigation 2003 112 12 1796 1808
15. Hotamisligil G. S., Inflammation and metabolic disorders Nature 2006 444 7121 860 867
16. Glass C. K., Rosenfeld M. G., The coregulator exchange in transcriptional functions of nuclear receptors Genes and Development 2000 14 2 121 141
17. Delerive P., De Bosscher K., Besnard S., Peroxisome proliferator- activated receptor negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF- B and AP-1 Journal of Biological Chemistry 1999 274 45 32048 32054
18. Ricote M., Li A. C., Willson T. M., Kelly C. J., Glass C. K., The peroxisome proliferator-activated receptor- is a negative regulator of macrophage activation Nature 1998 391 6662 79 82
19. Grun F., Blumberg B., Minireview: the case for obesogens Molecular Endocrinology 2009 23 8 1127 1134
20. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M., The chemokine system in diverse forms of macrophage activation and polarization Trends in Immunology 2004 25 12 677 686
21. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes Trends in Immunology 2002 23 11 549 555
22. Weisberg S. P., Hunter D., Huber R., CCR2 modulates inflammatory and metabolic effects of high-fat feeding Journal of Clinical Investigation 2006 116 1 115 124
23. Brake D. K., Smith E. O., Mersmann H., Smith C. W., Robker R. L., ICAM-1 expression in adipose tissue: effects of diet-induced obesity in mice American Journal of Physiology 2006 291 C1232 C1239
24. Patsouris D., Li P.-P., Thapar D., Chapman J., Olefsky J. M., Neels J. G., Ablation of CD11c-positive cells normalizes insulin sensitivity in obese insulin resistant animals Cell Metabolism 2008 8 4 301 309
25. Fujisaka S., Usui I., Bukhari A., Regulatory mechanisms for adipose tissue M1 and M2 macrophages in diet-induced obese mice Diabetes 2009 58 11 2574 2582
26. Lumeng C. N., DeYoung S. M., Bodzin J. L., Saltiel A. R., Increased inflammatory properties of adipose tissue macrophages recruited during diet-induced obesity Diabetes 2007 56 1 16 23
27. Tsuchiya K., Sakai H., Suzuki N., Chronic blockade of nitric oxide synthesis reduces adiposity and improves insulin resistance in high fat-induced obese mice Endocrinology 2007 148 10 4548 4556
28. Lumeng C. N., Bodzin J. L., Saltiel A. R., Obesity induces a phenotypic switch in adipose tissue macrophage polarization Journal of Clinical Investigation 2007 117 1 175 184
29. Geissmann F., Jung S., Littman D. R., Blood monocytes consist of two principal subsets with distinct migratory properties Immunity 2003 19 1 71 82
30. Swirski F. K., Libby P., Aikawa E., Ly-6Chi monocytes dominate hypercholesterolemia-associated monocytosis and give rise to macrophages in atheromata Journal of Clinical Investigation 2007 117 1 195 205
31. Ghanim H., Aljada A., Hofmeyer D., Syed T., Mohanty P., Dandona P., Circulating mononuclear cells in the obese are in a proinflammatory state Circulation 2004 110 12 1564 1571
32. Stout R. D., Jiang C., Matta B., Tietzel I., Watkins S. K., Suttles J., Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences Journal of Immunology 2005 175 1 342 349
33. Watkins S. K., Egilmez N. K., Suttles J., Stout R. D., IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo Journal of Immunology 2007 178 3 1357 1362
34. Odegaard J. I., Ricardo-Gonzalez R. R., Goforth M. H., Macrophage-specific PPAR controls alternative activation and improves insulin resistance Nature 2007 447 7148 1116 1120
35. Odegaard J. I., Ricardo-Gonzalez R. R., Red E. A., Alternative M2 activation of Kupffer cells by PPAR ameliorates obesity-induced insulin resistance Cell Metabolism 2008 7 6 496 507
36. You T., Nicklas B. J., Chronic inflammation: role of adipose tissue and modulation by weight loss Current Diabetes Reviews 2006 2 1 29 37
37. Stenholm S., Koster A., Alley D. E., Adipocytokines and the metabolic syndrome among older persons with and without obesitythe InCHIANTI Study. Clinical Endocrinology. In press
38. Sun X. J., Liu F., Phosphorylation of IRS proteins. Yin-Yang regulation of insulin signaling Vitamins and Hormones 2009 80 351 387
39. del Aguila L. F., Claffey K. P., Kirwan J. P., TNF- impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells American Journal of Physiology 1999 276 5 E849 E855
40. Nieto-Vazquez I., Fernandez-Veledo S., Kramer D. K., Vila-Bedmar R., Garcia-Guerra L., Lorenzo M., Insulin resistance associated to obesity: the link TNF-alpha Archives of Physiology and Biochemistry 2008 114 3 183 194
41. Prada P. O., Zecchin H. G., Gasparetti A. L., Western diet modulates insulin signaling, c-jun N-terminal kinase activity, and insulin receptor substrate-1ser307 phosphorylation in a tissue-specific fashion Endocrinology 2005 146 3 1576 1587
42. Yuan M., Konstantopoulos N., Lee J., Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk Science 2001 293 5535 1673 1677
43. Rui L., Yuan M., Frantz D., Shoelson S., White M. F., SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2 Journal of Biological Chemistry 2002 277 44 42394 42398
44. Kile B. T., Schulman B. A., Alexander W. S., Nicola N. A., Martin H. M. E., Hilton D. J., The SOCS box: a tale of destruction and degradation Trends in Biochemical Sciences 2002 27 5 235 241
45. Jiang C., Ting A. T., Seed B., PPAR- agonists inhibit production of monocyte inflammatory cytokines Nature 1998 391 6662 82 86
46. Shu H., Wong B., Zhou G., Activation of PPAR or reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells Biochemical and Biophysical Research Communications 2000 267 1 345 349
47. Castrillo A., Joseph S. B., Marathe C., Mangelsdorf D. J., Tontonoz P., Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages Journal of Biological Chemistry 2003 278 12 10443 10449
48. Joseph S. B., Castrillo A., Laffitte B. A., Mangelsdorf D. J., Tontonoz P., Reciprocal regulation of inflammation and lipid metabolism by liver X receptors Nature Medicine 2003 9 2 213 219
49. Neve B. P., Corseaux D., Chinetti G., PPAR agonists inhibit tissue factor expression in human monocytes and macrophages Circulation 2001 103 2 207 212
50. Lee C.-H., Chawla A., Urbiztondo N., Transcriptional repression of atherogenic inflammation: modulation by PPAR Science 2003 302 5644 453 457
51. Hevener A. L., Olefsky J. M., Reichart D., Macrophage PPAR is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones Journal of Clinical Investigation 2007 117 6 1658 1669
52. Ghisletti S., Huang W., Ogawa S., Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPAR Molecular Cell 2007 25 1 57 70
53. Clement K., Viguerie N., Poitou C., Weight loss regulates inflammation-related genes in white adipose tissue of obese subjects FASEB Journal 2004 18 14 1657 1669
54. Berg A. H., Combs T. P., Scherer P. E., ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism Trends in Endocrinology and Metabolism 2002 13 2 84 89
55. Punthakee Z., Delvin E. E., O'Loughlin J., Adiponectin, adiposity, and insulin resistance in children and adolescents Journal of Clinical Endocrinology and Metabolism 2006 91 6 2119 2125
56. Arita Y., Kihara S., Ouchi N., Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity Biochemical and Biophysical Research Communications 1999 257 1 79 83
57. Fernandes-Santos C., Carneiro R. E., de Souza Mendonca L., Aguila M. B., Mandarim-de-Lacerda C. A., Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet Nutrition 2009 25 7-8 818 827
58. Lemieux S., Despres J. P., Moorjani S., Are gender differences in cardiovascular disease risk factors explained by the level of visceral adipose tissue? Diabetologia 1994 37 8 757 764
59. Lonnqvist F., Thorne A., Large V., Arner P., Sex differences in visceral fat lipolysis and metabolic complications of obesity Arteriosclerosis, Thrombosis, and Vascular Biology 1997 17 7 1472 1480
60. Zappala G., Rechler M. M., IGFBP-3, hypoxia and TNF- inhibit adiponectin transcription Biochemical and Biophysical Research Communications 2009 382 4 785 789
61. Huang H., Park P.-H., McMullen M. R., Nagy L. E., Mechanisms for the anti-inflammatory effects of adiponectin in macrophages Journal of Gastroenterology and Hepatology 2008 23 supplement 1 S50 S53
62. Maeda N., Takahashi M., Funahashi T., PPAR ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein Diabetes 2001 50 9 2094 2099
63. Landrier J.-F., Gouranton E., El Yazidi C., Adiponectin expression is induced by vitamin E via a peroxisome proliferator-activated receptor -dependent mechanism Endocrinology 2009 150 12 5318 5325
64. Rong X., Li Y., Ebihara K., An adipose tissue-independent insulin-sensitizing action of telmisartan: a study in lipodystrophic mice Journal of Pharmacology and Experimental Therapeutics 2009 331 3 1096 1103
65. Leclercq I. A., Da Silva M. A., Schroyen B., Van Hul N., Geerts A., Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences Journal of Hepatology 2007 47 1 142 156
66. Bilzer M., Roggel F., Gerbes A. L., Role of Kupffer cells in host defense and liver disease Liver International 2006 26 10 1175 1186
67. Zhang D., Sun M., Samols D., Kushner I., STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6 Journal of Biological Chemistry 1996 271 16 9503 9509
68. Kamada Y., Tamura S., Kiso S., Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin Gastroenterology 2003 125 6 1796 1807
69. Sleyster E. C., Knook D. L., Relation between localization and function of rat liver Kupffer cells Laboratory Investigation 1982 47 5 484 490
70. Laskin D. L., Weinberger B., Laskin J. D., Functional heterogeneity in liver and lung macrophages Journal of Leukocyte Biology 2001 70 2 163 170
71. Lefkowitch J. H., Haythe J. H., Regent N., Kupffer cell aggregation and perivenular distribution in steatohepatitis Modern Pathology 2002 15 7 699 704
72. Guebre-Xabier M., Yang S., Lin H. Z., Schwenk R., Krzych U., Diehl A. M., Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage Hepatology 2000 31 3 633 640
73. Kremer M., Hines I. N., Milton R. J., Wheeler M. D., Favored T helper 1 response in a mouse model of hepatosteatosis is associated with enhanced T cell-mediated hepatitis Hepatology 2006 44 1 216 227
74. Neyrinck A. M., Cani P. D., Dewulf E. M., De Backer F., Bindels L. B., Delzenne N. M., Critical role of Kupffer cells in the management of diet-induced diabetes and obesity Biochemical and Biophysical Research Communications 2009 385 3 351 356
75. Rivera C. A., Adegboyega P., van Rooijen N., Tagalicud A., Allman M., Wallace M., Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis Journal of Hepatology 2007 47 4 571 579
76. Enomoto N., Takei Y., Yamashima S., Ikejima K., Kitamura T., Sato N., Protective effect of pioglitazone against endotoxin-induced liver injury through prevention of Kupffer cell sensitization AlcoholismClinical and Experimental Research 2005 29 216S 219S
77. Uchimura K., Nakamuta M., Enjoji M., Activation of retinoic X receptor and peroxisome proliferator-activated receptor- inhibits nitric oxide and tumor necrosis factor- production in rat Kupffer cells Hepatology 2001 33 1 91 99
78. Huang W., Metlakunta A., Dedousis N., Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance Diabetes 2010 59 2 347 357
79. Stienstra R., Saudale F., Duval C., Kupffer cells promote hepatic steatosis via interleukin-1 -dependent suppression of peroxisome proliferator-activated receptor activity Hepatology 2010 51 2 511 522
80. Woods C. G., Kosyk O., Bradford B. U., Time course investigation of PPAR -and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expression Toxicology and Applied Pharmacology 2007 225 3 267 277
81. Punthakee Z., Scully L. J., Guindi M. M., Ooi T. C., Liver fibrosis attributed to lipid lowering medications: two cases Journal of Internal Medicine 2001 250 3 249 254
82. Uno M., Kurita S., Misu H., Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis Hepatology 2008 48 1 109 118
83. Gonzalez F. J., The peroxisome proliferator-activated receptor (PPAR ): role in hepatocarcinogenesis Molecular and Cellular Endocrinology 2002 193 1-2 71 79
84. Kang K., Reilly S. M., Karabacak V., Adipocyte-derived Th2 cytokines and myeloid PPAR regulate macrophage polarization and insulin sensitivity Cell Metabolism 2008 7 6 485 495
85. Bonds D. E., Larson J. C., Schwartz A. V., Risk of fracture in women with type 2 diabetes: the women's health initiative observational study Journal of Clinical Endocrinology and Metabolism 2006 91 9 3404 3410
86. Hwang D.-K., Choi H.-J., The relationship between low bone mass and metabolic syndrome in Korean women Osteoporosis International 2010 21 3 425 431
87. Schwartz A. V., Sellmeyer D. E., Women, type 2 diabetes, and fracture risk Current Diabetes Reports 2004 4 5 364 369
88. Vestergaard P., Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetesa meta-analysis Osteoporosis International 2007 18 4 427 444 (Pubitemid 46354916)
89. Reid I. R., Leptin deficiencylessons in regional differences in the regulation of bone mass Bone 2004 34 3 369 371
90. Thrailkill K. M., Lumpkin C. K. Jr., Bunn R. C., Kemp S. F., Fowlkes J. L., Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues American Journal of Physiology 2005 289 5 E735 E745
91. Shinoda Y., Yamaguchi M., Ogata N., Regulation of bone formation by adiponectin through autocrine/paracrine and endocrine pathways Journal of Cellular Biochemistry 2006 99 1 196 208
92. Berner H. S., Lyngstadaas S. P., Spahr A., Adiponectin and its receptors are expressed in bone-forming cells Bone 2004 35 4 842 849
93. Ealey K. N., Kaludjerovic J., Archer M. C., Ward W. E., Adiponectin is a negative regulator of bone mineral and bone strength in growing mice Experimental Biology and Medicine 2008 233 12 1546 1553
94. Richards J. B., Valdes A. M., Burling K., Perks U. C., Spector T. D., Serum adiponectin and bone mineral density in women Journal of Clinical Endocrinology and Metabolism 2007 92 4 1517 1523
95. Williams G. A., Wang Y., Callon K. E., In vitro and in vivo effects of adiponectin on bone Endocrinology 2009 150 8 3603 3610
96. Schett G., Kiechl S., Weger S., High-sensitivity C-reactive protein and risk of nontraumatic fractures in the bruneck study Archives of Internal Medicine 2006 166 22 2495 2501
97. Manolagas S. C., Jilka R. L., Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis New England Journal of Medicine 1995 332 5 305 311
98. Ershler W. B., Keller E. T., Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty Annual Review of Medicine 2000 51 245 270
99. Nanes M. S., Tumor necrosis factor- : molecular and cellular mechanisms in skeletal pathology Gene 2003 321 1-2 1 15
100. Ding C., Parameswaran V., Udayan R., Burgess J., Jones G., Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study Journal of Clinical Endocrinology and Metabolism 2008 93 5 1952 1958
101. Horowitz M. C., Lorenzo J. A., The origins of osteoclasts Current Opinion in Rheumatology 2004 16 4 464 468
102. Manolagas S. C., Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis Endocrine Reviews 2000 21 2 115 137
103. Ferron M., Hinoi E., Karsenty G., Ducy P., Osteocalcin differentially regulates cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice Proceedings of the National Academy of Sciences of the United States of America 2008 105 13 5266 5270
104. Nomiyama T., Perez-Tilve D., Ogawa D., Osteopontin mediates obesity-induced adipose tissue macrophage infiltration and insulin resistance in mice Journal of Clinical Investigation 2007 117 10 2877 2888
105. Lee N. K., Sowa H., Hinoi E., Endocrine regulation of energy metabolism by the skeleton Cell 2007 130 3 456 469
106. Grey A., Skeletal consequences of thiazolidinedione therapy Osteoporosis International 2008 19 2 129 137
107. Rzonca S. O., Suva L. J., Gaddy D., Montague D. C., Lecka-Czernik B., Bone is a target for the antidiabetic compound rosiglitazone Endocrinology 2004 145 1 401 406
108. Wan Y., Chong L.-W., Evans R. M., PPAR- regulates osteoclastogenesis in mice Nature Medicine 2007 13 12 1496 1503
109. Akune T., Ohba S., Kamekura S., PPAR insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors Journal of Clinical Investigation 2004 113 6 846 855
110. Cock T.-A., Back J., Elefteriou F., Enhanced bone formation in lipodystrophic PPAR hyp/hyp mice relocates haematopoiesis to the spleen EMBO Reports 2004 5 10 1007 1012
111. Robertson K. M., Norgard M., Windahl S. H., Cholesterol-sensing receptors, liver X receptor and, have novel and distinct roles in osteoclast differentiation and activation Journal of Bone and Mineral Research 2006 21 8 1276 1287
112. Chan B. Y., Gartland A., Wilson P. J. M., PPAR agonists modulate human osteoclast formation and activity in vitro Bone 2007 40 1 149 159